Ignite Creation Date:
2024-05-06 @ 1:04 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03925818
Status:
TERMINATED
Last Update Posted:
2019-04-26
First Post:
2019-04-19
Brief Title:
Low Dose Bismuth Versus Lactobacillus Reuteri for H Pylori Eradication
Sponsor:
Università degli Studi di Sassari
Organization:
Università degli Studi di Sassari
Study Overview
Official Title:
Twice-a-day PPI Tetracycline Metronidazolequadruple Therapy With Pylera or Lactobacillus Reuteri for Treatment naïve or for Retreatment of H Pylori Two Randomized Pilot Studies
Status:
TERMINATED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lactobacillus reuteri Gastrus was not anymore available in the region
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LactoBismu
Brief Summary:
This study investigates the efficacy of a bid quadruple therapy containing Pylera or L reuteri for H pylori infection
Detailed Description:
Bismuth metronidazole and tetracycline yielded high cure rates for H pylori infection Earlier studies suggested that the bismuth quadruple therapy may be effective when given twice-a-day rather than qid and that bid therapy was associated with fewer side effects The addition of the probiotic Lactobacillus reuteri Gastrus to Lactobacillus reuteri Gastrus that has been shown to increase the cure rates by 10-14 In another study bismuth supplementation with L reuteri DSM 17938 in a modified low dose quadruple therapy provided good eradication rates 933 95 CI 85-99 in clinical practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None